WO2022236255A2 - Composés hétérocycliques en tant qu'inhibiteurs de kinase - Google Patents

Composés hétérocycliques en tant qu'inhibiteurs de kinase Download PDF

Info

Publication number
WO2022236255A2
WO2022236255A2 PCT/US2022/072061 US2022072061W WO2022236255A2 WO 2022236255 A2 WO2022236255 A2 WO 2022236255A2 US 2022072061 W US2022072061 W US 2022072061W WO 2022236255 A2 WO2022236255 A2 WO 2022236255A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkylene
pharmaceutically acceptable
tautomer
stereoisomer
Prior art date
Application number
PCT/US2022/072061
Other languages
English (en)
Other versions
WO2022236255A3 (fr
Inventor
Son Minh Pham
Jayakanth Kankanala
Jeremy D. Pettigrew
Chris P. Miller
Brahmam PUJALA
Bhawana BHATT
Varun Kumar
Anjan Kumar NAYAK
Amit Shivraj SHETE
Sanjeev SONI
Original Assignee
Nuvation Bio Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc. filed Critical Nuvation Bio Inc.
Publication of WO2022236255A2 publication Critical patent/WO2022236255A2/fr
Publication of WO2022236255A3 publication Critical patent/WO2022236255A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Definitions

  • This disclosure relates generally to therapeutics which play a crucial role in the control of the cell cycle and more particularly, compounds that inhibit cyclin-dependent kinases (CDK).
  • CDK cyclin-dependent kinases
  • the disclosure also provides pharmaceutically acceptable compositions comprising compounds of the present disclosure and methods of using said compositions in the treatment of diseases associated with these pathways.
  • the cell cycle is a period between the successive divisions of a cell. During this period, the contents of the cell must be accurately replicated.
  • the processes that permit the cell to divide are very precisely controlled by a multitude of enzymatic reactions amongst which the protein kinase-triggered protein phosphorylation plays a major role.
  • there are four main stages/phases of cell cycle namely the Gap-1 (G1) phase, Synthesis (S) phase, Gap-2 (G2) and Mitosis (M) phases.
  • An extended phase of Gap-1 phase is coined as Gap-0 (G0) phase or Resting phase (Cancers 2014, 6, 2224-2242).
  • Cyclin- dependent kinases constitute a heterodimeric family of serine/threonine protein kinases involved in cell cycle and transcription. They include two main groups: cell cycle CDK and transcriptional CDK. The functionality of CDK depends on specific interactions with regulatory proteins named cyclins which form heterodimeric complexes with their partners. These complexes are important regulators of the cellular processes, especially in the cell cycle progression.
  • CDK5 is the prototype of atypical CDK: it is activated by the non-cyclin proteins p35 (or Cdk5R1) and p39 (or Cdk5R2) and has unique post-mitotic functions in neuronal biology, angiogenesis and cell differentiation.
  • Proliferative signals induce the transition from the GO or G1 phases into S phase through the activation of the structurally related CDK4 and CDK6 [Development, 2013;140 (15):3079-93, Biochem Pharmacol 2012;84(8):985-93, Nature 2014;510(7505):393-6].
  • the binding of cyclin D to CDK4 and to CDK6 promotes the phosphorylation of the transcriptional repressor retinoblastoma protein (RB1).
  • CDK hyperactivity is often observed in cancer, reflecting their prominent role in cell cycle and transcription regulation.
  • cancer cells the process of cell division becomes unregulated, resulting in uncontrolled growth that leads to the development of a tumor.
  • a number of mechanisms contribute to the dysregulation of the cell cycle in malignant cells, including the amplification and hyperactivity of CDK4/6, or their genomic instability, which might cause CDK4/6 to become oncogenic drivers of cell replication. Usurping these mechanisms, cancer cells can continue to replicate by triggering the G1 to S phase transition. This process appears to be facilitated by a shortening of the G1 phase.
  • CDK4/6 antagonizes intrinsic tumor suppression mechanisms including cell senescence and apoptosis, which further augments the growth of a tumor.
  • Cancer cells also upregulate other CDK and cyclins and decrease suppressive mechanisms such as intrinsic CDK inhibitors and tumor suppressor proteins. The overall effect of this type of cell cycle dysregulation is malignant cell proliferation and the development of cancer (Clinical Breast Cancer, 2016, 1526-8209).
  • CDK inhibitors have been reported (such as in WO2011101409 and WO201 1101417) or clinically developed. Flavopiridol and R-Roscovitine (Seliciclib), were the first generation of pan-CDK inhibitors with anti-tumor activity attributed to down- regulation of CDK9-mediated anti-apoptotic proteins, especially Mcl-1. Recently, a new generation of CDK inhibitors have been developed, advanced to clinical trials, and approved for certain types of cancer.
  • CDK4/6 inhibitors for the treatment of hyper-proliferative diseases preferably have at least one advantageous property selected from selectivity, potency, stability, pharmacodynamic properties and safety profile.
  • a novel class of CDK4/6 inhibitors is provided herein.
  • a method of treating cancer in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a compound as detailed herein.
  • a method of modulating CDK4/6 in an individual comprising administering to the individual a compound detailed herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
  • a method of modulating CDK4/6 and one or more of CDK1, CDK2, and CDK9 in an individual comprising administering to the individual a compound detailed herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
  • kits comprising a compound detailed herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, are also provided. Kits may optionally include instructions for use, such as instructions for use in any of the methods detailed herein, for example, for use in the treatment of cancer. A compound as detailed herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is also provided for the manufacture of a medicament for the treatment of cancer. DETAILED DESCRIPTION
  • the term “about” refers to a variation of ⁇ 1%, ⁇ 3%, ⁇ 5%, or ⁇ 10% of the value specified.
  • “about 50” can in some embodiments includes a range of from 45 to 55.
  • the term “about” can include one or two integers greater than and/or less than a recited integer at each end of the range.
  • the term “about” is intended to include values, e.g., weight percentages, proximate to the recited range that are equivalent in terms of the functionality of the individual ingredient, the composition, or the embodiment.
  • the singular forms “a” and “the” include plural references unless the context clearly dictates otherwise.
  • reference to “the compound” includes a plurality of such compounds and includes reference to one or more compounds and equivalents thereof known to those skilled in the art.
  • alkyl refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (C 1-20 alkyl or C 1 -C 20 alkyl), 1 to 8 carbon atoms (C 1-8 alkyl or C 1 -C 8 alkyl), 1 to 6 carbon atoms (C 1-6 alkyl or C 1 -C 6 alkyl), or 1 to 4 carbon atoms (C 1-4 alkyl or C 1 -C 4 alkyl).
  • alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl.
  • alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e.
  • -(CH 2 ) 3 CH 3 sec-butyl (i.e. -CH(CH 3 )CH 2 CH 3 ), iso-butyl (i.e. -CH 2 CH(CH 3 ) 2 ) and tert-butyl (i.e. -C(CH 3 ) 3 ); and “propyl” includes n-propyl (i.e. -(CH 2 ) 2 CH 3 ) and isopropyl (i.e. - CH(CH 3 ) 2 ).
  • Haloalkyl refers to an unbranched or branched alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a halogen.
  • a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached.
  • Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen.
  • Examples of haloalkyl include difluoromethyl (-CHF 2 ) and trifluoromethyl (-CF 3 ).
  • the alkenyl group may be in “cis” or “trans” configurations, or alternatively in “E” or “Z” configurations.
  • Particular alkenyl groups are those having 2 to 20 carbon atoms (C 2-20 alkenyl or C 2 -C 20 alkenyl), having 2 to 8 carbon atoms (C 2-8 alkenyl or C 2 -C 8 alkenyl), having 2 to 6 carbon atoms (C 2-6 alkenyl or C 2 -C 6 alkenyl), or having 2 to 4 carbon atoms (C 2-4 alkenyl or C 2 -C 4 alkenyl).
  • alkenyl examples include, but are not limited to, groups such as ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2- methylbuta-1,3-dienyl, homologs and isomers thereof, and the like.
  • Alkylene refers to the same residues as alkyl, but having bivalency. Particular alkylene groups are those having 1 to 6 carbon atoms (C 1 - 6 alkylene or C 1 -C 6 alkylene), 1 to 5 carbon atoms (C 1-5 alkylene or C 1 -C 5 alkylene), 1 to 4 carbon atoms (C 1 -4 alkylene or C 1 -C 4 alkylene) or 1 to 3 carbon atoms (C 1-3 alkylene or C 1 -C 3 alkylene).
  • alkylene examples include, but are not limited to, groups such as methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -), butylene (-CH 2 CH 2 CH 2 CH 2 -), and the like.
  • Alkoxy refers to the group “-O-alkyl”. Examples of alkoxy groups include, without limitation, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec- butoxy, npentoxy, n-hexoxy and 1,2-dimethylbutoxy.
  • Alkynyl refers to an unsaturated linear or branched hydrocarbon chain or combination thereof, having at least one site of acetylenic unsaturation (i.e., having at least one moiety of the formula C ⁇ C).
  • Particular alkynyl groups are those having 2 to 20 carbon atoms (C 2-20 alkynyl or C 2 -C 20 alkynyl), having 2 to 8 carbon atoms (C 2-8 alkynyl or C 2 -C 8 alkynyl), having 2 to 6 carbon atoms (C 2-6 alkynyl or C 2 -C 6 alkynyl), or having 2 to 4 carbon atoms (C 2-4 alkynyl or C 2 -C 4 alkynyl).
  • alkynyl examples include, but are not limited to, groups such as ethynyl (or acetylenyl), prop-1-ynyl, prop-2-ynyl (or propargyl), but-1-ynyl, but-2-ynyl, but-3-ynyl, homologs and isomers thereof, and the like.
  • Aryl refers to and includes polyunsaturated aromatic hydrocarbon groups.
  • Aryl may contain additional fused rings (e.g., from 1 to 3 rings).
  • the aryl group contains from 6 to 14 annular carbon atoms (“C 6 -C 14 aryl”),.
  • Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and anthryl.
  • Aryl does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl, the resulting ring system is heteroaryl. If one or more aryl groups are fused with a heterocyclyl, the resulting ring system is heterocyclyl.
  • Cycloalkyl refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fused, bridged and spiro ring systems.
  • the term “cycloalkyl” includes cycloalkenyl groups (i.e., the cyclic group having at least one double bond) and carbocyclic fused ring systems having at least one sp 3 carbon atom (i.e., at least one non-aromatic ring).
  • cycloalkyl has from 3 to 20 ring carbon atoms (C 3-20 cycloalkyl or C 3 -C 20 cycloalkyl), 3 to 12 ring carbon atoms (C 3-12 cycloalkyl or C 3 -C 12 cycloalkyl), 3 to 10 ring carbon atoms (C 3-10 cycloalkyl or C 3 -C 10 cycloalkyl), 3 to 8 ring carbon atoms (C 3-8 cycloalkyl or C 3 -C 8 cycloalkyl), or 3 to 6 ring carbon atoms (C 3-6 cycloalkyl or C 3 -C 6 cycloalkyl).
  • Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • cycloalkyl is intended to encompass any non-aromatic cyclic alkyl ring which may be fused to an aryl ring, regardless of the attachment to the remainder of the molecule.
  • Halo or “halogen” refers to elements of the Group 17 series having atomic number 9 to 85. Preferred halo groups include fluoro, chloro, bromo and iodo.
  • Heteroaryl refers to an aromatic group having a single ring, multiple rings or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • heteroaryl includes 1 to 20 ring carbon atoms, 3 to 12 ring carbon atoms, or 3 to 8 carbon ring atoms, and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen and sulfur.
  • heteroaryl includes 5- to 12- membered, 5- to 10- membered ring systems, 5- to 7- membered ring systems, or 5- to 6- membered ring systems, each independently having 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen and sulfur.
  • Any aromatic ring, having a single or multiple fused rings, containing at least one heteroatom, is considered a heteroaryl regardless of the attachment to the remainder of the molecule (i.e., through any one of the fused rings).
  • Heteroaryl does not encompass or overlap with aryl as defined above.
  • Heterocyclyl refers to a saturated or partially unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur.
  • heterocyclyl includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond), bicyclic heterocyclic groups, such as bridged-heterocyclyl groups, fused-heterocyclyl groups and spiro-heterocyclyl groups.
  • Any non- aromatic ring containing at least one heteroatom is considered a heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom).
  • the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to an aryl or heteroaryl ring, regardless of the attachment to the remainder of the molecule.
  • heterocyclyl has 2 to 20 ring carbon atoms, 2 to 12 ring carbon atoms, 2 to 10 ring carbon atoms, 2 to 8 ring carbon atoms, 3 to 12 ring carbon atoms, 3 to 8 ring carbon atoms, or 3 to 6 ring carbon atoms; and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen.
  • heteroaryl includes 3- to 12- membered, 5- to 10- membered ring systems, 5- to 7- membered ring systems, or 5- to 6- membered ring systems, each independently having 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen and sulfur.
  • heterocyclyl also includes “spiroheterocyclyl” when there are two positions for substitution on the same carbon atom.
  • the term “bicyclic heterocyclic” encompasses fused- heterocyclyl groups.
  • Optionally substituted unless otherwise specified means that a group may be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4 or 5) of the substituents listed for that group in which the substituents may be the same of different, provided that the group’s normal valence is not exceeded.
  • an optionally substituted group has one substituent.
  • an optionally substituted group has two substituents.
  • an optionally substituted group has three substituents.
  • an optionally substituted group has four substituents.
  • an optionally substituted group has 1 to 2, 2 to 5, 3 to 5, 2 to 3, 2 to 4, 3 to 4, 1 to 3, 1 to 4 or 1 to 5 substituents.
  • CDK refers to one or more cyclin-dependent kinases.
  • CDK4/6 refers to both CDK4 and CDK6. Thus, inhibitors of CDK4/6 inhibit both CDK4 and CDK6.
  • a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
  • a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
  • treatment is an approach for obtaining beneficial or desired results including clinical results.
  • beneficial or desired results include, but are not limited to, one or more of the following: decreasing symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, delaying the progression of the disease, and/or prolonging survival of individuals.
  • beneficial or desired results include shrinking a tumor (reducing tumor size); decreasing the growth rate of the tumor (such as to suppress tumor growth); reducing the number of cancer cells; inhibiting, retarding or slowing to some extent and preferably stopping cancer cell infiltration into peripheral organs; inhibiting (slowing to some extent and preferably stopping) tumor metastasis; inhibiting tumor growth; preventing or delaying occurrence and/or recurrence of tumor; and/or relieving to some extent one or more of the symptoms associated with the cancer.
  • beneficial or desired results include preventing or delaying occurrence and/or recurrence, such as of unwanted cell proliferation.
  • “delaying development of a disease” means to defer, hinder, slow, retard, stabilize, and/or postpone development of the disease (such as cancer). This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, a late stage cancer, such as development of metastasis, may be delayed.
  • an “effective dosage” or “effective amount” of compound or salt thereof or pharmaceutical composition is an amount sufficient to effect beneficial or desired results.
  • beneficial or desired results include results such as eliminating or reducing the risk, lessening the severity of, or delaying the onset of the disease, including biochemical, histological and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease.
  • beneficial or desired results include ameliorating, palliating, lessening, delaying or decreasing one or more symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, enhancing effect of another medication such as via targeting, delaying the progression of the disease, and/or prolonging survival.
  • an effective amount comprises an amount sufficient to cause a tumor to shrink and/or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation.
  • an effective amount is an amount sufficient to delay development.
  • an effective amount is an amount sufficient to prevent or delay occurrence and/or recurrence.
  • an effective amount can be administered in one or more administrations, in the case of cancer, the effective amount of the drug or composition may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
  • An effective dosage can be administered in one or more administrations.
  • an effective dosage of compound or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. It is intended and understood that an effective dosage of a compound or salt thereof, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an “effective dosage” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
  • the term “individual” is a mammal, including humans.
  • An individual includes, but is not limited to, human, bovine, horse, feline, canine, rodent, or primate.
  • the individual is human.
  • the individual (such as a human) may have advanced disease or lesser extent of disease, such as low tumor burden.
  • the individual is at an early stage of a proliferative disease (such as cancer).
  • the individual is at an advanced stage of a proliferative disease (such as an advanced cancer).
  • pharmaceutically acceptable or “pharmacologically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
  • Pharmaceutically acceptable carriers or excipients have preferably met the required standards of toxicological and manufacturing testing and/or are included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
  • “Pharmaceutically acceptable salts” are those salts which retain at least some of the biological activity of the free (non- salt) compound and which can be administered as drugs or pharmaceuticals to an individual.
  • Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, tartaric acid and the like; (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base.
  • a metal ion e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion
  • coordinates with an organic base e.g
  • Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine and the like.
  • Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
  • Further examples of pharmaceutically acceptable salts include those listed in Berge et al., Pharmaceutical Salts, J. Pharm. Sci. 1977 Jan;66(1):1-19.
  • Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound of the disclosure in its free acid or base form with a suitable organic or inorganic base or acid, respectively, and isolating the salt thus formed during subsequent purification.
  • excipient means an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound of the disclosure as an active ingredient.
  • a drug or pharmaceutical such as a tablet containing a compound of the disclosure as an active ingredient.
  • Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression/encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending/gelling agent, or wet granulation agent.
  • X 1 is CR 3 or N;
  • X 2 is CR 3 or N;
  • X 3 is CR 3 or N;
  • A is C 3 -C 6 cycloalkyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or C 6 aryl, each of which is optionally substituted with one or more R 5 ;
  • L is a bond, -CR 11 R 12 -, -O-, -S-, -S(O) 2 -, -C(O)-, -NR 10 -, -S(O) 2 NR 10 -, or - NR 10 SO 2 -;
  • B is hydrogen, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocyclyl, 5- to 7- membered heteroaryl, or C 6 aryl, each of which is optionally substituted with one or more R 6 ;
  • C is C 3 -C 6 cycloalkyl, 5- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or C 6 aryl, each of which is optionally substituted with one or more R 5 , wherein C is fused to D;
  • D is C 3 -C 6 cycloalkyl, 3- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or C 6 aryl, each of which is optionally substituted with one or more R 6 ;
  • R 1 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 8 alkoxy, C 3- C 12 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 - C 14 aryl, -(C 1 -C 3 alkylene)(C 3 - C 12 cycloalkyl), -(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), -C(O)R 10 , -(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) or -(C 1 -C 3 alkylene)(C 6 -C 14 aryl), wherein R 1 is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, -OR 13 , -NR 13 R 14 , -C(
  • each R 10 is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, -(C 1 - C 3 alkylene)(C 3 -C 6 cycloalkyl), C 6 -C 14 aryl, 5- to 6-membered heteroaryl or 3- to 6- membered heterocyclyl, each of which is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, -CN, -OR 15 , -NR 15 R 16 , and C 1 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of
  • R 11 and R 12 are each independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, -(C 1 - C 3 alkylene)(C 3 -C 6 cycloalkyl), C 6 -C 14 aryl, 5- to 6-membered heteroaryl or 3- to 6- membered heterocyclyl, each of which is independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, -CN, -OR 15 , -NR 15 R 16 , and C 1 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, and oxo, or R 11 and R 12 are taken together with the atom to which they attached to form a 3- to 6- membered heterocyclyl optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, and C 1 -C 6 alkyl optionally substitute
  • R 13 and R 14 are each independently hydrogen or C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, -OR 15 , -NR 15 R 16 , and oxo, or R 13 and R 14 are taken together with the atom to which they attached to form a 3- to 6- membered heterocyclyl optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, and C 1 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, and oxo; and
  • R 15 and R 16 are each independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 - C 6 alkynyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, and oxo, or R 15 and R 16 are taken together with the atom to which they attached to form a 3- to 6- membered heterocyclyl optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, and C 1 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, and oxo; l is 0, 1, or 2; p and q are each independently 0, 1, 2 or 3; and n is 0, 1, 2, 3 or 4, provided that at least one of (1)
  • At least one of X 1 , X 2 , and X 3 is N or CR 3 , wherein R 3 is -CN,
  • R 2 is C 1 -C 6 alkyl substituted with one or more halogen
  • R 2 or R 1 and R 2 are taken together with the atom or atoms to which they are attached to form a C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, or C 6 -C 14 aryl, each of which is independently optionally substituted with one or more substituents selected from the group consisting of C 1 -C 6 alkyl, -OH, oxo, and halogen.
  • a compound of Formula provides a compound of Formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X 1 , X 2 , X 3 , A, B, L, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , l, m, n, p, and q are as detailed herein for Formula (J).
  • a compound of Formula provides a compound of Formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X 1 , X 2 , X 3 , C, D, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , l, n, p, and q are as detailed herein for Formula (J).
  • X 1 is N. In some embodiments, X 1 is CR 3 . In some embodiments, X 1 is CR 3 , wherein R 3 is -CN. In some embodiments, X 2 is N. In some embodiments, X 2 is CR 3 . In some embodiments, X 2 is CR 3 , wherein R 3 is -CN. In some embodiments, X 3 is N. In some embodiments, X 3 is CR 3 . In some embodiments, X 3 is CR 3 , wherein R 3 is -CN.
  • each R 3 is independently C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, halogen, or -OH.
  • each R 3 is independently C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy or halogen.
  • each R 3 is independently fluoro, chloro, methyl, trifluoromethyl, trifluoromethoxy, methoxy, and cyclopropyl.
  • R 3 is halogen.
  • At least one of X 1 , X 2 , and X 3 is N or CR 3 , wherein R 3 is -CN.
  • l is 0. In some embodiments, / is 1 or 2. In some embodiments, l is 1. In some embodiments, l is 2.
  • each R 4 is independently C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, halogen, or -OH.
  • each R 4 is independently C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy or halogen.
  • each R 4 is independently fluoro, chloro, methyl, trifluoromethyl, trifluoromethoxy, methoxy, and cyclopropyl. In some embodiments, R 4 is halogen. In some embodiments, l is 1 and R 4 is halogen.
  • l is 1 and R 4 is -CN.
  • a compound of Formula (J) is of Formula (J-1), (I- 1 ), or (II- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
  • n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some emboidments, n is 4. In some embodiments, n is 0 or 1. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 0, 1, 2, or 3. In some emboidments, n is 1, 2, or 3.
  • each R 2 is independently C 1 -C 6 alkyl, oxo, -C(O)R 10 , or -CN. In some embodiments, each R 2 is independently C 1 -C 6 alkyl, oxo, or halogen. In some embodiments, each R 2 is oxo. In some embodiments, each R 2 is independently -NR 11 R 12 . In some embodiments, each R 2 is -CN. In some embodiments, each R 2 is independently -C(O)R 10 . In some embodiments, R 2 is -C(O)R 10 , wherein R 10 is C 1 -C 6 alkyl such as methyl.
  • R 2 is -C(O)NR 11 R 12 .
  • R 2 is halogen, such as fluoro.
  • R 2 is C 1 -C 6 alkyl, such methyl.
  • R 2 is H.
  • each R 2 is independently oxo or C 1 -C 6 alkyl such as methyl.
  • each R 2 is independently oxo or C 1 -C 6 alkyl such as methyl; and n is 1 or 2.
  • each R 2 is independently oxo or C 1 -C 6 alkyl such as methyl; and n is 1.
  • each R 2 is independently oxo or C 1 -C 6 alkyl such as methyl; and n is 2. In some embodiments, R 2 is C 1 -C 6 alkyl such as methyl. In some embodiments, R 2 is C 1 -C 6 alkyl such as methyl; and n is 1. In some embodiments, each R 2 is independently -C(O)R 10 , wherein R 10 is C 1 -C 6 alkyl such as methyl. In some embodiments, each R 2 is independently -C(O)R 10 , wherein R 10 is C 1 -C 6 alkyl such as methyl; and n is 1. In some embodiments, each R 2 is oxo; and n is 1 or 2.
  • each R 2 is oxo; and n is 1. In some embodiments, each R 2 is oxo; and n is 2. In some embodiments, each R 2 is independently oxo or -CN. In some embodiments, each R 2 is independently oxo or -CN; and n is 2. In some embodiments, R 2 is independently methyl, oxo, -C(O)CH 3 , or -CN. In some embodiments, one R 2 is oxo and one R 2 is C 1 -C 6 alkyl substituted with one or more halogen; and n is 2.
  • a compound of Formula (J) is of Formula (J-2), (1-2), or (II-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
  • two R 2 are taken together with the atom or atoms to which they are attached to form a C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, or C 6 -C 14 aryl, each of which is independently optionally substituted with one or more substituents selected from the group consisting of C 1 -C 6 alkyl, -OH, oxo, and halogen.
  • two R 2 are attached to a same carbon atom and are taken together with the atom to form a C 3 -C 6 cycloalkyl.
  • a compound of Formula (J) is of Formula (J-3), (1-3), or (II-3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. wherein m is 1, 2, 3, or 4.
  • a compound of Formula (J) is of Formula (J-4), (1-4), or (II-4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
  • R 1 and R 2 are taken together with the atoms to which they are attached to form a C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, or C 6 - C 14 aryl, each of which is independently optionally substituted with one or more substituents selected from the group consisting of C 1 -C 6 alkyl, -OH, oxo, and halogen.
  • R 1 and R 2 are taken together with the atoms to which they are attached to form
  • a compound of Formula (J) is of Formula (J-5), (1-5), or (II-5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
  • a compound of Formula (J) is of Formula (J-6), (1-6), or (II-6), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
  • R 1 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 8 alkoxy, C 3 - C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 - C 14 aryl, -C(O)R 10 , -(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), -(C 1 -C 3 alkylene)(3- to 12- membered heterocyclyl), -(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) or -(C 1 -C 3 alkylene)(C 6 -C 14 aryl), each of which is independently optionally substituted with one or more substituents selected from the group consisting of halogen
  • R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, 3- to 12- membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, -C(O)R 10 , -(C 1 - C 3 alkylene)(C 3 -C 6 cycloalkyl), -(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), -(C 1 - C 3 alkylene)(5- to 10-membered heteroaryl) or -(C 1 -C 3 alkylene)(C 6 -C 14 aryl), each of which is unsubstituted.
  • R 1 is C 2 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 - C 8 alkoxy, C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, -(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), -C(O)R 10 , or -(C 1 -C 3 alkylene)(C6-C 14 aryl), each of which independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, -OR 13 , -NR 13 R 14 , -C(O)R 13 , -CN, C 3 -C 8 cycloalkyl, and C 1 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting
  • R 1 is C 2 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 8 alkoxy, C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, or -C(O)R 10 , each of which independently optionally substituted with one or more substituents selected from the group consisting of halogen, oxo, -OR 13 , -NR 13 R 14 , -C(O)R 13 , -CN, C 3 -C 8 cycloalkyl, and C 1 -C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of oxo, -OH or halogen.
  • R 1 is hydrogen, C 1 -C 6 alkyl, -C(O)R 10 , -(C 1 -C 3 alkylene)(C 3 - C 6 cycloalkyl), -(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl), or C 3 -C 6 cycloalkyl, each of which is optionally substituted with halogen, oxo, -NH 2 .
  • R 1 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclopentyl, cyclohexyl or cyclopropyl-methyl.
  • R 1 is isopropyl.
  • R 1 is C 1 -C 6 alkyl.
  • R 1 is C 2 -C 6 alkyl.
  • R 1 is selected from the group consisting of wherein the wavy lines denote attachment points to the rest of the molecule.
  • A is C 3 -C 6 cycloalkyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl or C 6 aryl, each of which is unsubstituted.
  • A is C 3 -C 6 cycloalkyl, 4- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl or C 6 aryl, each of which is optionally substituted with one or more R 5 .
  • A is C 6 aryl optionally substituted with one or more R 5 .
  • A is phenyl optionally substituted with one or more R 5 .
  • A is 5- to 7-membered heteroaryl optionally substituted with one or more R 5 .
  • A is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazolyl, thiazolyl, oxazolyl, isooxazolyl or imidazolyl, each of which is optionally substituted with one or more R 5 .
  • A is 4- to 7-membered heterocyclyl optionally substituted with one or more R 5 .
  • A is piperidinyl, pyrrolidinyl, azetidinyl, dihydropyridine, or pyridone, each of optionally substituted with one or more R 5 .
  • A is C 3 - C 6 cycloalkyl optionally substituted with one or more R 5 .
  • A is cyclohexyl or cyclopentyl, each of which is optionally substituted with one or more R 5 .
  • A is phenyl, pyridinyl, pyrimidinyl, pyrazolyl, thiazolyl, oxazolyl, isooxazolyl, imidazolyl, piperidinyl, pyrrolidinyl, azetidinyl, pyridone, cyclohexyl, or cyclopentyl, each of which is unsubstituted.
  • A is phenyl, pyridinyl, pyrimidinyl, pyrazolyl, thiazolyl, oxazolyl, isooxazolyl, imidazolyl, piperidinyl, pyrrolidinyl, azetidinyl, dihydropyridine, pyridone, cyclohexyl, or cyclopentyl, each of which is optionally substituted with one or more R 5 .
  • B is hydrogen, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocyclyl, 5- to 7- membered heteroaryl, or C 6 aryl, each of which is optionally substituted with one or more R 6 .
  • B is C 3 -C 6 cycloalkyl, 3- to 7-membered heterocyclyl, 5- to 7- membered heteroaryl, or C 6 aryl, each of which is unsubstituted.
  • B is hydrogen.
  • B is 3- to 7-membered heterocyclyl optionally substituted with one or more R 6 .
  • B is diazepanyl, azepanyl, piperazinyl, piperidinyl, pyrrolidinyl or azetidinyl, each of which is optionally substituted with one or more R 6 .
  • B is 5- to 7-membered heteroaryl optionally substituted with one or more R 6 .
  • B is imidazolyl or pyrazolyl, each of which is optionally substituted with one or more R 6 .
  • B is phenyl optionally substituted with one or more R 6 .
  • B is C 3 -C 6 cycloalkyl optionally substituted with one or more R 6 .
  • B is cyclopentyl, cyclohexyl, or cycloheptyl, each of which is optionally substituted with one or more R 6 .
  • B is hydrogen, diazepanyl, azepanyl, piperazinyl, piperidinyl, pyrrolidinyl, azetidinyl, imidazolyl, pyrazolyl, phenyl, cyclopentyl, cyclohexyl, or cycloheptyl, each of which is unsubstituted.
  • B is hydrogen, diazepanyl, azepanyl, piperazinyl, piperidinyl, pyrrolidinyl, azetidinyl, imidazolyl, pyrazolyl, phenyl, cyclopentyl, cyclohexyl, or cycloheptyl, each of which is optionally substituted with one or more R 6 .
  • L is a bond, -CH 2 -, -NH-, -0-, -S-, -S(O) 2 -, -CO-, -NCH3-, -S(O) 2 NH-,or - NHS(O) 2 -.
  • L is a bond, -CH 2 -, -NH-, - 0-, or -S-.
  • L is a bond.
  • L is -CH 2 -.
  • L is -NH-.
  • L is -S-.
  • L is -0-. In some embodiments, L is -S(O) 2 -. In some embodiments, L is -C(O)-. In some embodiments, L is -NCH3-. In some embodiments, L is -NHS(O) 2 -. In some embodiments, L is -CR 11 R 12 -. In some embodiments, L is -NR 10 -. In some embodiments, L is -NR 10 S(O) 2 -. In some embodiments, L is -S(O) 2 NR 10 -. In some embodiments, L is -S(O) 2 NH-. In some embodiments, L is - NHS(O) 2 -.
  • t is 0. In some embodiments, t is 1. In some embodiments, t is 2. In some embodiments, t' is 0. In some embodiments, t' is 1. In some embodiments, t is 1 and t' is 1.
  • D is fused with C to form a 7- to 12- membered bicyclic ring having at least one aromatic ring, wherein C and D are optionally substituted with one or more R 5 and R 6 .
  • D is fused with C to form a 7- to 12- membered bicyclic ring having at least one aromatic ring and at least one heteroatom selected from the group consisting of N, O, and S, wherein C and D are optionally substituted with with one or more R 5 and R 6 .
  • D is fused with C to form a 7- to 12- membered bicyclic ring having at least one aromatic ring and at least one nitrogen atom, wherein C and D are optionally substituted with with one or more R 5 and R 6 .
  • D is fused with C to form a 7- to 12- membered bicyclic ring having at least one aromatic ring and at least one nitrogen atom, wherein C and D are optionally substituted with with one or more R 5 and R 6 .
  • R 7 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, -C(O)R 10 , each of which (except hydrogen) is optionally substituted by halogen, oxo, -OR 13 , -NR 13 R 14 , -C(O)R 13 ,
  • R 7 is hydrogen, methyl, ethyl, isopropyl, cyclopropyl, -C(O)CH 2 NHCH 3 , or -CH 2 CH 2 OH.
  • p is 0. In some embodiments, p is 0 or 1. In some embodiments, p is 0, 1, or 2.
  • each R 5 is independently C 1 -C 6 alkyl, halogen, oxo, -CN, -OR 10 , -NR 11 R 12 , -C(O)R 10 , -C(O)NR 11 R 12 , C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, -(C 1 - C 3 alkylene)OR 10 , -(C 1 -C 3 alkylene)NR 11 R 12 , -(C 1 -C 3 alkylene)C(O)R 10 , -(C 1 - C 3 alkylene)(C 3 -C 6 cycloalkyl), -(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), each of which is optionally substituted by halogen, oxo, -OR 13 , -NR 13 R 14 ,
  • each R 5 is independently -CN, halogen, methoxy, oxo, trifluoromethoxy, - NH(CH 3 ), -N(CH 3 ) 2 , -(CH 2 )NH(CH 3 ), -(CH 2 )NH 2 , -(CH 2 )N(CH 3 ) 2 , -C(O)NH 2 , - C(O)N(CH 3 ) 2 , methyl, ethyl, isopropyl, cyclopropyl, -CH 2 OH, -CH 2 0CH 3 , - NH(CH2)2N(CH2CH 3 )2, -O(CH 2 )2N(CH 2 CH 3 )2, or trifluoromethyl.
  • each R 5 is independently -CN, halogen, methoxy, oxo, trifluoromethoxy, -NH(CH 3 ), - N(CH 3 ) 2 , -(CH 2 )NH(CH 3 ), -(CH 2 )NH 2 , -(CH 2 )N(CH 3 ) 2 , -C(O)NH 2 , -C(O)N(CH 3 ) 2 , methyl, ethyl, isopropyl, n-propyl, cyclopropyl, -CH 2 OH, -CH 2 OCH 3 , -NH(CH 2 ) 2 N(CH 2 CH 3 ) 2 , -
  • q is 0. In some embodiments, q is 0 or 1. In some embodiments, q is 0, 1, or 2.
  • each R 6 is independently C 1 -C 6 alkyl, halogen, oxo, -CN, -NR 11 R 12 , -C(O)R 10 , C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, -(C 1 -C 3 alkylene)OR 10 , -(C 1 - C 3 alkylene)NR 11 R 12 , each of which is optionally substituted by halogen, oxo, -OR 13 , -NR 13 R 14 , -C(O)R 13 , -CN, -(C 1 -C 3 alkylene)OR 13 , -(C 1 -C 3 alkylene)NR 13 R 14 , -(C 1 - C 3 alkylene)C(O)R 13 , C 3 -C 8 cycloalkyl, or C 1 -C 6 alkyl, or C 1 -C 6 alkyl, halogen, oxo,
  • each R 6 is independently ethyl, methyl, isopropyl, pyrrolidinyl, -N(CH 3 ) 2 , -CH 2 OH, oxo, - C(O)CH 2 NHCH 3 , -CH 2 CH 2 OH, difluoroethyl, -CH 2 N(CH 3 ) 2 , -OH, or -C(O)CH 2 0H.
  • each R 6 is independently ethyl, methyl, isopropyl, pyrrolidinyl, cyclopropyl, methoxy, -N(CH 3 ) 2 , -NHCH 3 , -CH 2 OH, oxo, -C(O)CH 2 NHCH 3 , -CH 2 CH 2 OH, difluoroethyl, -CH 2 N(CH 3 ) 2 , -CH 2 NH 2 , -OH, -C(O)CH 2 0H, -C(O)CH 2 N(CH 3 ) 2 , -C(O)N(CH 3 ) 2 , -
  • Z is selected from the group consisting of:
  • Z is
  • Z is selected from the group consisting of:
  • R 1 any specific value of R 1 detailed herein for a compound of Formula (J) as well as all related formulae may be combined with any other specific value for one or more of the variables Z, X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , l, m, and n the same as if each and every combination were specifically and individually listed.
  • salts of compounds referred to herein such as pharmaceutically acceptable salts.
  • the invention also includes any or all of the stereochemical forms, including any enantiomeric or diastereomeric forms, and any tautomers or other forms of the compounds described. It is understood that individual enantiomers and diastereomers are provided herein and their corresponding structures can be readily determined.
  • a compound as detailed herein may in one aspect be in a purified form and compositions comprising a compound in purified forms are detailed herein.
  • Compositions comprising a compound as detailed herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing are provided, such as compositions of substantially pure compounds.
  • a composition containing a compound as detailed herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing is in substantially pure form.
  • substantially pure intends a composition that contains no more than 35% impurity, wherein the impurity denotes a compound other than the compound comprising the majority of the composition or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
  • a composition of substantially pure compound or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing is provided wherein the composition contains no more than 25%, 20%, 15%, 10%, or 5% impurity.
  • compositions of substantially pure compound or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing wherein the composition contains or no more than 3%, 2%, 1% or 0.5% impurity.
  • the compounds depicted herein may be present as salts even if salts are not depicted and it is understood that the present disclosure embraces all salts and solvates of the compounds depicted here, as well as the non-salt and non-solvate form of the compound, as is well understood by the skilled artisan.
  • the salts of the compounds provided herein are pharmaceutically acceptable salts. Where one or more tertiary amine moiety is present in the compound, the N-oxides are also provided and described.
  • tautomeric forms may be present for any of the compounds described herein, each and every tautomeric form is intended even though only one or some of the tautomeric forms may be explicitly depicted.
  • the tautomeric forms specifically depicted may or may not be the predominant forms in solution or when used according to the methods described herein.
  • the present disclosure also includes any or all of the stereochemical forms, including any enantiomeric or diastereomeric forms of the compounds described.
  • the structure or name is intended to embrace all possible stereoisomers of a compound depicted. All forms of the compounds are also embraced by the invention, such as crystalline or non- crystalline forms of the compounds.
  • Compositions comprising a compound of the invention are also intended, such as a composition of substantially pure compound, including a specific stereochemical form thereof, or a composition comprising mixtures of compounds of the invention in any ratio, including two or more stereochemical forms, such as in a racemic or non-racemic mixture.
  • the invention also intends isotopically-labeled and/or isotopically-enriched forms of compounds described herein.
  • the compounds herein may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the compound is isotopically-labeled, such as an isotopically-labeled compound of the formula (I) or variations thereof described herein, where a fraction of one or more atoms are replaced by an isotope of the same element.
  • Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C 13 N, 15 O, 17 O, 32 P, 35 S, 18 F, 36 C1.
  • Certain isotope labeled compounds e.g. 3 H and 14 C
  • are useful in compound or substrate tissue distribution studies. Incorporation of heavier isotopes such as deuterium ( 2 H) can afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life, or reduced dosage requirements and, hence may be preferred in some instances.
  • Isotopically-labeled compounds of the present invention can generally be prepared by standard methods and techniques known to those skilled in the art or by procedures similar to those described in the accompanying Examples substituting appropriate isotopically- labeled reagents in place of the corresponding non-labeled reagent.
  • the disclosure also includes any or all metabolites of any of the compounds described.
  • the metabolites may include any chemical species generated by a biotransformation of any of the compounds described, such as intermediates and products of metabolism of the compound, such as would be generated in vivo following administration to a human.
  • Articles of manufacture comprising a compound described herein, or a salt or solvate thereof, in a suitable container are provided.
  • the container may be a vial, jar, ampoule, preloaded syringe, i.v. bag, and the like.
  • the compounds detailed herein are orally bioavailable.
  • the compounds may also be formulated for parenteral (e.g ., intravenous) administration.
  • One or several compounds described herein can be used in the preparation of a medicament by combining the compound or compounds as an active ingredient with a pharmacologically acceptable carrier, which are known in the art.
  • a pharmacologically acceptable carrier which are known in the art.
  • the carrier may be in various forms.
  • the manufacture of a medicament is for use in any of the methods disclosed herein, e.g., for the treatment of cancer.
  • the compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter (such as the schemes provided in the Examples below).
  • the symbols when used in the formulae depicted are to be understood to represent those groups described above in relation to the formulae herein.
  • a particular enantiomer of a compound this may be accomplished from a corresponding mixture of enantiomers using any suitable conventional procedure for separating or resolving enantiomers.
  • diastereomeric derivatives may be produced by reaction of a mixture of enantiomers, e.g., a racemate, and an appropriate chiral compound. The diastereomers may then be separated by any convenient means, for example by crystallization and the desired enantiomer recovered. In another resolution process, a racemate may be separated using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described.
  • compositions of any of the compounds detailed herein are embraced by this disclosure.
  • the present disclosure includes pharmaceutical compositions comprising a compound as detailed herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic or organic acid.
  • Pharmaceutical compositions may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration or a form suitable for administration by inhalation.
  • a compound as detailed herein may in one aspect be in a purified form and compositions comprising a compound in purified forms are detailed herein.
  • Compositions comprising a compound as detailed herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing are provided, such as compositions of substantially pure compounds.
  • a composition containing a compound as detailed herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing is in substantially pure form.
  • the compounds herein are synthetic compounds prepared for administration to an individual.
  • compositions are provided containing a compound in substantially pure form.
  • present disclosure embraces pharmaceutical compositions comprising a compound detailed herein and a pharmaceutically acceptable carrier.
  • methods of administering a compound are provided. The purified forms, pharmaceutical compositions and methods of administering the compounds are suitable for any compound or form thereof detailed herein.
  • a compound detailed herein or salt thereof may be formulated for any available delivery route, including an oral, mucosal (e.g., nasal, sublingual, vaginal, buccal or rectal), parenteral (e.g., intramuscular, subcutaneous or intravenous), topical or transdermal delivery form.
  • oral, mucosal e.g., nasal, sublingual, vaginal, buccal or rectal
  • parenteral e.g., intramuscular, subcutaneous or intravenous
  • topical or transdermal delivery form e.g., topical or transdermal delivery form.
  • a compound or salt thereof may be formulated with suitable carriers to provide delivery forms that include, but are not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, gums, dispersions, suppositories, ointments, cataplasms (poultices), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal spray or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), solutions and elixirs.
  • suitable carriers include, but are not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, gums, dispersions, suppositories, ointments, cataplasms (poultic
  • One or several compounds described herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing can be used in the preparation of a formulation, such as a pharmaceutical formulation, by combining the compound or compounds, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, as an active ingredient with a pharmaceutically acceptable carrier, such as those mentioned above.
  • a pharmaceutically acceptable carrier such as those mentioned above.
  • the carrier may be in various forms.
  • pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, and salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants.
  • Formulations comprising the compound may also contain other substances which have valuable therapeutic properties.
  • Pharmaceutical formulations may be prepared by known pharmaceutical methods. Suitable formulations can be found, e.g., in Remington’s Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 20 th ed. (2000), which is incorporated herein by reference.
  • Compounds as described herein may be administered to individuals in a form of generally accepted oral compositions, such as tablets, coated tablets, and gel capsules in a hard or in soft shell, emulsions or suspensions.
  • carriers which may be used for the preparation of such compositions, are lactose, corn starch or its derivatives, talc, stearate or its salts, etc.
  • Acceptable carriers for gel capsules with soft shell are, for instance, plant oils, wax, fats, semisolid and liquid poly-ols, and so on.
  • pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, and salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants.
  • any of the compounds described herein can be formulated in a tablet in any dosage form described, for example, a compound as described herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, can be formulated as a 10 mg tablet.
  • compositions comprising a compound provided herein are also described.
  • the composition comprises a compound or salt thereof and a pharmaceutically acceptable carrier or excipient.
  • a composition of substantially pure compound is provided.
  • Compounds and compositions detailed herein such as a pharmaceutical composition containing a compound of any formula provided herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier or excipient, may be used in methods of administration and treatment as provided herein.
  • the compounds and compositions may also be used in in vitro methods, such as in vitro methods of administering a compound or composition to cells for screening purposes and/or for conducting quality control assays.
  • the methods comprise administration of a compound detailed herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, as a monotherapy.
  • a method of treating a disease in an individual comprising administering an effective amount of a compound disclosed herein or a variation thereof, to the individual.
  • a method of treating a proliferative disease in an individual comprising administering an effective amount of a compound disclosed herein to the individual.
  • a method of treating cancer in an individual comprising administering an effective amount of a compound disclosed herein to the individual.
  • the compound is administered to the individual according to a dosage and/or method of administration described herein.
  • the cancer in the individual has one or more mutations or amplification or overexpression of the genes encoding cyclins or of the genes encoding the CDK or loss of endogenous INK4 inhibitors by gene deletion, mutation, or promoter hypermethylation, or other genetic events leading to overactivity of one or more of CDK1, CDK2, CDK4, CDK6 and CDK9.
  • the cancer in the individual has one or more mutations or amplification or overexpression of the genes encoding cyclins or of the genes encoding the CDK or loss of endogenous INK4 inhibitors by gene deletion, mutation, or promoter hypermethylation, or other genetic events leading to overactivity of CDK4/6 and one or more of CDK1, CDK2, and CDK9.
  • a method of treating a cancer in an individual comprising (a) selecting the individual for treatment based on (i) the presence of phosphorylation of the retinoblastoma ( Rb ) protein in the cancer, or (ii) presence of mutations or amplification or overexpression of CDK4 or CDK6 in the cancer, and administering an effective amount of a compound disclosed herein to the individual.
  • the cancer is assayed for the expression of phosphorylated Rb.
  • the cancer is assayed for the expression of CDK4 or CDK6.
  • the CDK4 or CDK6 gene of the cancer is sequenced to detect the one or more mutations or amplifications.
  • the CDK4 or CDK6 gene is sequenced by biopsying the cancer and sequencing the CDK4 or CDK6 gene from the biopsied cancer.
  • the CDK4 or CDK6 gene is sequenced by sequencing circulating-tumor DNA (ctDNA) from the individual.
  • a compound disclosed herein is used to treat an individual having a proliferative disease, such as cancer as described herein.
  • the individual is at risk of developing a proliferative disease, such as cancer.
  • the individual is determined to be at risk of developing cancer based upon one or more risk factors.
  • the risk factor is a family history and/or gene associated with cancer.
  • a compound disclosed herein is believed to be effective for treating a variety of diseases and disorders.
  • a compound disclosed herein may be used to treat a proliferative disease, such as cancer.
  • the cancer is a solid tumor.
  • the cancer is any of adult and pediatric oncology, myxoid and round cell carcinoma, locally advanced tumors, metastatic cancer, human soft tissue sarcomas, including Ewing's sarcoma, cancer metastases, including lymphatic metastases, squamous cell carcinoma, particularly of the head and neck, esophageal squamous cell carcinoma, oral carcinoma, blood cell malignancies, including multiple myeloma, leukemias, including acute lymphocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, and hairy cell leukemia, effusion lymphomas (body cavity based lymphomas), thymic lymphoma, cutaneous T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cancer of the adrenal cortex, ACTH-producing tumors, lung cancer, including small cell carcinoma and nonsmall cell cancers, breast cancer
  • the cancer is defined by a molecular characteristic.
  • the cancer is an estrogen receptor-posistive breast cancer.
  • the breast cancer is triple negative breast cancer.
  • the cancer is a KRAS-mutant non-small cell lung cancer.
  • the cancer is mantle cell lymphoma defined by a translocation involving CCND1 resulting in cyclin D1 overexpression.
  • the compounds and compositions described herein cause G 1 -S cell cycle arrest in a cell (such as a cancer cell).
  • the cancer cell is a cancer cell from any of the cancer types described herein.
  • arrested cells enter a state of apoptosis.
  • arrested cells enter a state of senescence.
  • provided herein is a method of causing G 1 -S checkpoint arrest in a cell comprising administering an effective amount of a compound disclosed herein to the cell.
  • the G 1 -S cell cycle arrest occurs in about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more of cells in a cell population. In some embodiments, the G 1 -S cell cycle arrest occurs in up to about 99%, up to about 98%, up to about 97%, up to about 96%, up to about 95%, up to about 90%, up to about 85%, or up to about 80% of cells in the cell population.
  • a method of inducing senescence in a cell comprising administering an effective amount of a compound disclosed herein to the cell.
  • senescence is induced in about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more of cells in a cell population.
  • senescence is induced in up to about 99%, up to about 98%, up to about 97%, up to about 96%, up to about 95%, up to about 90%, up to about 85%, or up to about 80% of cells in the cell population.
  • apoptosis is induced in about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more of cells in a cell population.
  • apoptosis is induced in up to about 99%, up to about 98%, up to about 97%, up to about 96%, up to about 95%, up to about 90%, up to about 85%, or up to about 80% of cells in the cell population.
  • CDK4 or CDK6 is inhibited by about 10% or more, about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 75% or more, about 80% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more.
  • CDK4 or CDK6 is inhibited up to about 99%, up to about 98%, up to about 97%, up to about 96%, up to about 95%, up to about 90%, up to about 85%, up to about 80%, up to about 70%, or up to about 60%.
  • the activity of CDK4 or CDK6 is measured according to a kinase assay.
  • provided herein is a method of inhibiting one or more of CDK1, CDK2, CDK4, CDK6, and CDK9 in a cell comprising administering an effective amount of a compound disclosed herein to the cell.
  • one or more of CDK1, CDK2, CDK4, CDK6, and CDK9 is inhibited by about 10% or more, about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 75% or more, about 80% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more.
  • one or more of CDK1, CDK2, CDK4, CDK6, and CDK9 is inhibited up to about 99%, up to about 98%, up to about 97%, up to about 96%, up to about 95%, up to about 90%, up to about 85%, up to about 80%, up to about 70%, or up to about 60%.
  • the activity of one or more of CDK1, CDK2, CDK4, CDK6, and CDK9 is measured according to a kinase assay.
  • a method of inhibiting CDK4 or CDK6 comprising contacting CDK4 or CDK6 with an effective amount of a compound disclosed herein or a variation thereof.
  • a compound disclosed herein binds to CDK4 or CDK6 with an IC 50 of less than 1 ⁇ M, less than 900 nM, less than 800 nM, less than 700 nM, less than 600 nM, less than 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, or less than 0.5 nM.
  • a compound disclosed herein binds to CDK4 or CDK6 with an IC 50 between 0.1 nM and 1 nM, between 1 nM and 5 nM, between 5 nM and 10 nM, between 10 nM and 50 nM, between 50 nM and 100 nM, beween 100 nM and 200 nM, between 200 nM and 300 nM, between 300 nM and 400 nM, betwee 400 nM and 500 nM, between 500 nM and 600 nM, between 600 nM and 700 nM, between 700 nM and 800 nM, between 800 nM and 900 nM, or between 900 nM and 1 ⁇ M.
  • the IC 50 is measured according to a kinase assay.
  • the IC 50 is measured according to a cell proliferation assay.
  • provided herein is a method of inhibiting one or more of CDK1, CDK2, CDK4, CDK6, and CDK9 comprising contacting one or more of CDK1, CDK2, CDK4, CDK6, and CDK9 with an effective amount of a compound disclosed herein or a variation thereof.
  • a compound disclosed herein binds to one or more of CDK1, CDK2, CDK4, CDK6, and CDK9 with an IC 50 of less than 1 ⁇ M, less than 900 nM, less than 800 nM, less than 700 nM, less than 600 nM, less than 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, or less than 0.5 nM.
  • a compound disclosed herein binds to one or more of CDK1, CDK2, CDK4, CDK6, and CDK9 with an IC 50 between 0.1 nM and 1 nM, between 1 nM and 5 nM, between 5 nM and 10 nM, between 10 nM and 50 nM, between 50 nM and 100 nM, beween 100 nM and 200 nM, between 200 nM and 300 nM, between 300 nM and 400 nM, betwee 400 nM and 500 nM, between 500 nM and 600 nM, between 600 nM and 700 nM, between 700 nM and 800 nM, between 800 nM and 900 nM, or between 900 nM and 1 ⁇ M.
  • the IC 50 is measured according to a kinase assay.
  • the IC 50 is measured according to a cell proliferation assay.
  • provided herein is a method of modulating CDK4/6 in an individual, comprising administering to the individual a compound disclosed herein or a variation thereof. In some embodiments, provided herein is a method of modulating CDK4 and CDK 6 in an individual, comprising administering to the individual a compound disclosed herein or a variation thereof. In some embodiments, provided herein is a method of modulating CDK4/6 and one or more of CDK1, CDK2, and CDK9 in an individual, comprising administering to the a compound disclosed herein or a variation thereof.
  • a method of modulating CDK4 and CDK 6 and one or more of CDK1, CDK2, and CDK9 in an individual comprising administering to the individual a compound disclosed herein or a variation thereof.
  • a compound disclosed herein binds to one or more of CDK4/6 with an IC 50 of less than 1 ⁇ M, less than 900 nM, less than 800 nM, less than 700 nM, less than 600 nM, less than 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, or less than 0.5 nM.
  • a compound disclosed herein binds to one or more of CDK4 and CDK6 with an IC 50 of less than 1 ⁇ M, less than 900 nM, less than 800 nM, less than 700 nM, less than 600 nM, less than 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 50 nM, less than 10 nM, less than 5 nM, less than 1 nM, or less than 0.5 nM.
  • a compound disclosed herein binds to one or more of CDK1, CDK2, CDK4, CDK6, and CDK9 with an IC 50 between 0.1 nM and 1 nM, between 1 nM and 5 nM, between 5 nM and 10 nM, between 10 nM and 50 nM, between 50 nM and 100 nM, beween 100 nM and 200 nM, between 200 nM and 300 nM, between 300 nM and 400 nM, betwee 400 nM and 500 nM, between 500 nM and 600 nM, between 600 nM and 700 nM, between 700 nM and 800 nM, between 800 nM and 900 nM, or between 900 nM and 1 ⁇ M.
  • the IC 50 is measured according to a kinase assay.
  • the IC 50 is measured according to a cell proliferation assay.
  • a compound disclosed herein may enhance the antitumour immunity by increasing the functional capacity of tumour cells to present antigen or by reducing the immunosuppressive T Reg population by suppressing their proliferation.
  • a method of inhibiting the proliferation of a cell comprising contacting the cell with an effective amount of a compound disclosed herein or a variation thereof.
  • a compound disclosed herein is effective in inhibiting the proliferation of the cell with an EC 50 of less than 5 ⁇ M, less than 2 ⁇ M, less than 1 ⁇ M, less than 900 nM, less than 800 nM, less than 700 nM, less than 600 nM, less than 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, or less than 50 nM.
  • a compound disclosed herein is effective in inhibiting the proliferation of the cell with an EC 50 between 10 nM and 20 nM, between 20 nM and 50 nM, between 50 nM and 100 nM, between 100 nM and 500 nM, between 500 nM and 1 ⁇ M, beween 1 ⁇ M and 2 ⁇ M, or between 2 ⁇ M and 5 ⁇ M.
  • the EC 50 is measured according to a cell proliferation assay.
  • a compound disclosed herein may affect the immune system. Accordingly, a compound disclosed herein may be used in combination with other anti- cancer agents or immunotherapies.
  • a method of treating a disease in an individual comprising administering an effective amount of a compound disclosed herein and an additional therapeutic agent to the individual.
  • the additional therapeutic agent is a cancer immunotherapy agent or an endocrine therapy agent or a chemotherapeutic agent.
  • the disease is a proliferative disease such as cancer.
  • the additional therapeutic agent is a cancer immunotherapy agent.
  • the additional therapeutic agent is an immunostimulatory agent.
  • the additional therapeutic agent targets a checkpoint protein (for example an immune checkpoint inhibitor).
  • the additional therapeutic agent is effective to stimulate, enhance or improve an immune response against a tumor.
  • a combination therapy for the treatment of a disease such as cancer.
  • a method of treating a disease in an individual comprising administering an effective amount of a compound disclosed herein in combination with a radiation therapy.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of an endocrine therapy agent.
  • the endocrine therapy is antiestrogen therapy.
  • the endocrine therapy is a selective estrogen receptor degrader (SERD, such as fulvestrant).
  • SESD selective estrogen receptor degrader
  • the endocrine therapy is an aromatase inhibitor (such as letrozole).
  • the combination of a CDK4/6 inhibitor and endocrine therapy causes enhancement of Gl-S cell-cycle arrest.
  • the combination of a CDK4/6 inhibitor and endocrine therapy causes enhanced entry into a senescent state.
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the endocrine therapy agent.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the endocrine therapy agent.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a second chemotherapeutic agent.
  • the chemotherapeutic agent is another kinase inhibitor.
  • a compound disclosed herein is administered prior to, after, or simultaneously co- administered with the second chemotherapeutic agent.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the second chemotherapeutic agent.
  • chemotherapeutic agents that can be used in combination with a compound disclosed herein include DNA-targeted agents, a DNA alkylating agent (such as cyclophosphamide, mechlorethamine, chlorambucil, melphalan, dacarbazine, or nitrosoureas), a topoisomerase inhibitor (such as a Topoisomerase I inhibitor (e.g., irinotecan or topotecan) or a Topoisomerase II inhibitor (e.g., etoposide or teniposide)), an anthracycline (such as daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, or valrubicin), a histone deacetylase inhibitor (such as vorinostat or romidepsin), a bromodomain inhibitor, other epigenetic inhibitors, a taxane (such as paclit
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a kinase inhibitor (such as bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, vismodegib, or ibrutinib).
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the kinase inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the kinase inhibitor.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a DNA damaging agent.
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the DNA damaging agent.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the DNA damaging agent.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a DNA alkylating agent (such as cyclophosphamide, mechlorethamine, chlorambucil, melphalan, dacarbazine, or nitrosoureas).
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the DNA alkylating agent.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the DNA alkylating agent.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a topoisomerase inhibitor (such as a Topoisomerase I inhibitor (e.g., irinotecan or topotecan) or a Topoisomerase II inhibitor (e.g., etoposide or teniposide)).
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the topoisomerase inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the topoisomerase inhibitor.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of an anthracycline (such as daunombicin, doxorubicin, epimbicin, idarubicin, mitoxantrone, or valmbicin).
  • an anthracycline such as daunombicin, doxorubicin, epimbicin, idarubicin, mitoxantrone, or valmbicin.
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the anthracycline.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the anthracycline.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a histone deacetylase inhibitor (such as vorinostat or romidepsin).
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the histone deacetylase inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the histone deacetylase inhibitor.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a taxane (such as paclitaxel or docetaxel).
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the taxane.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the taxane.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a nucleotide analog or precursor analog (such as azacitidine, azathioprine, capecitabine, cytarabine, doxifluridine, 5-fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, or tioguanine).
  • a nucleotide analog or precursor analog such as azacitidine, azathioprine, capecitabine, cytarabine, doxifluridine, 5-fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, or tioguanine.
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the nucleotide analog or precursor analog.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the nucleotide analog or precursor analog.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a platinum-based chemotherapeutic agent (such as cisplatin, carboplatin, or oxaliplatin).
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the platinum-based chemotherapeutic agent.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the platinum-based chemotherapeutic agent.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of pemetrexed.
  • Formula (J a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the pemetrexed.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the pemetrexed.
  • a method of treating a disease in an individual comprising (a) administering an effective amount a compound disclosed herein and (b) administering an effective amount of a Bruton’s tyrosine kinase (BTK) inhibitor.
  • BTK tyrosine kinase
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the BTK inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the BTK inhibitor.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a PI3K or Akt inhibitor.
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the PI3K or Akt inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the PI3K or Akt inhibitor.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a DNA damage repair (DDR) pathway inhibitor.
  • DDR DNA damage repair
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the DDR pathway inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the DDR pathway inhibitor.
  • inhibitors of the DDR pathway include poly(ADP-ribose) polymerase (PARP) inhibitors (such as olaparib, rucaparib, niraparib, or talazoparib), ataxia telangiectasia mutated (ATM) protein inhibitors, ataxia telangiectasia and Rad3 -related (ATR) protein inhibitors, checkpoint kinase 1 (Chk1) inhibitors, or combinations thereof.
  • PARP poly(ADP-ribose) polymerase
  • ATM telangiectasia mutated
  • ATR Rad3 -related
  • Chk1 checkpoint kinase 1
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a PARP inhibitor (such as olaparib, rucaparib, niraparib, or talazoparib).
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the PARP inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the PARP inhibitor.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of an ATM protein inhibitor.
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the ATM protein inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the ATM protein inhibitor.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of an ATR protein inhibitor.
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the ATR protein inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the ATR protein inhibitor.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of an Chk1 inhibitor.
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the Chk1 inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the Chk1 inhibitor.
  • a method of treating a disease in an individual comprising (a) administering an effective amount of a compound disclosed herein and (b) administering an effective amount of a further CDK4/6 inhibitor.
  • a compound disclosed herein is administered prior to, after, or simultaneously co-administered with the further CDK4/6 inhibitor.
  • a compound disclosed herein is administered 1 or more hours (such as 2 or more hours, 4 or more hours, 8 or more hours, 12 or more hours, 24 or more hours, or 48 or more hours) prior to or after the further CDK4/6 inhibitor.
  • a combination therapy in which a compound disclosed herein is coadministered (which may be separately or simultaneously) with one or more additional agents that are effective in stimulating immune responses to thereby further enhance, stimulate or upregulate immune responses in a subject.
  • a method for stimulating an immune response in a subject comprising administering to the subject a compound disclosed herein and one or more immuno stimulatory antibodies, such as an anti-PD-1 antibody, an anti-PD-L1 antibody and/or an anti-CTLA-4 antibody, such that an immune response is stimulated in the subject, for example to inhibit tumor growth.
  • the subject is administered a compound disclosed herein and an anti-PD-1 antibody.
  • the subject is administered a compound disclosed herein and an anti-PD-L1 antibody.
  • the subject is administered a compound disclosed herein and an anti-CTLA-4 antibody.
  • the immuno stimulatory antibody e.g., anti-PD-1, anti-PD-L1 and/or anti-CTLA-4 antibody
  • the immunostimulatory antibody is a human antibody.
  • the immunostimulatory antibody can be, for example, a chimeric or humanized antibody (e.g., prepared from a mouse anti-PD-1, anti-PD-L1 and/or anti-CTLA-4 antibody).
  • the present disclosure provides a method for treating a proliferative disease (e.g., cancer), comprising administering a compound disclosed herein and an anti-PD-1 antibody to a subject.
  • a compound disclosed herein is administered at a subtherapeutic dose
  • the anti-PD-1 antibody is administered at a subtherapeutic dose
  • the present disclosure provides a method for altering an adverse event associated with treatment of a hyperproliferative disease with an immunostimulatory agent, comprising a compound disclosed herein and a subtherapeutic dose of anti-PD-1 antibody to a subject.
  • the subject is human.
  • the anti-PD- 1 antibody is a human sequence monoclonal antibody.
  • the present invention provides a method for treating a hyperproliferative disease (e.g., cancer), comprising administering a compound disclosed herein and an anti-PD-L1 antibody to a subject.
  • a compound disclosed herein is administered at a subtherapeutic dose
  • the anti-PD-L1 antibody is administered at a subtherapeutic dose
  • the present invention provides a method for altering an adverse event associated with treatment of a hyperproliferative disease with an immunostimulatory agent, comprising administering a compound disclosed herein and a subtherapeutic dose of anti-PD- L1 antibody to a subject.
  • the subject is human.
  • the anti-PD-L1 antibody is a human sequence monoclonal antibody.
  • the combination of therapeutic agents discussed herein can be administered concurrently as a single composition in a pharmaceutically acceptable carrier, or concurrently as separate compositions each in a pharmaceutically acceptable carrier.
  • the combination of therapeutic agents can be administered sequentially.
  • an anti-CTLA-4 antibody and a compound disclosed herein can be administered sequentially, such as anti-CTLA-4 antibody being administered first and a compound disclosed herein second, or a compound disclosed herein being administered first and anti-CTLA-4 antibody second.
  • an anti-PD-1 antibody and a compound disclosed herein can be administered sequentially, such as anti-PD-1 antibody being administered first and a compound disclosed herein second, or a compound disclosed herein being administered first and anti-PD-1 antibody second.
  • an anti-PD-L1 antibody and a compound disclosed herein can be administered sequentially, such as anti-PD-L1 antibody being administered first and a compound disclosed herein second, a compound disclosed herein being administered first and anti-PD-L1 antibody second.
  • the combination of a compound disclosed herein can be further combined with an immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines.
  • an immunogenic agent such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines.
  • a compound disclosed herein can also be further combined with standard cancer treatments.
  • a compound disclosed herein can be effectively combined with chemotherapeutic regimens. In these instances, it is possible to reduce the dose of other chemotherapeutic reagent administered with the combination of the instant disclosure.
  • Other combination therapies with a compound disclosed herein include radiation, surgery, or hormone deprivation.
  • Angiogenesis inhibitors can also be combined with a compound disclosed herein. Inhibition of angiogenesis leads to tumor cell death, which can be a source of tumor antigen fed into host antigen presentation pathways.
  • a compound disclosed herein can be used in conjunction with anti-neoplastic antibodies.
  • treatment with an anti-cancer antibody or an anti-cancer antibody conjugated to a toxin can lead to cancer cell death (e.g., tumor cells) which would potentiate an immune response mediated by CTLA-4, PD-1, PD-L1 or a compound disclosed herein.
  • a treatment of a hyperproliferative disease can include an anti-cancer antibody in combination with a compound disclosed herein and anti-CTLA-4 and/or anti-PD-1 and/or anti-PD-L1 antibodies, concurrently or sequentially or any combination thereof, which can potentiate anti-tumor immune responses by the host.
  • Other antibodies that can be used to activate host immune responsiveness can be further used in combination with a compound disclosed herein.
  • a compound disclosed herein can be combined with an anti-CD73 therapy, such as an anti-CD73 antibody.
  • the dose of a compound administered to an individual may vary with the particular compound or salt thereof, the method of administration, and the particular disease, such as type and stage of cancer, being treated.
  • the amount of the compound or salt thereof is a therapeutically effective amount.
  • the effective amount of the compound may in one aspect be a dose of between about 0.01 and about 100 mg/kg.
  • Effective amounts or doses of the compounds of the invention may be ascertained by routine methods, such as modeling, dose escalation, or clinical trials, taking into account routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease to be treated, the subject’s health status, condition, and weight.
  • An exemplary dose is in the range of about from about 0.7 mg to 7 g daily, or about 7 mg to 350 mg daily, or about 350 mg to 1.75 g daily, or about 1.75 to 7 g daily.
  • Any of the methods provided herein may in one aspect comprise administering to an individual a pharmaceutical composition that contains an effective amount of a compound provided herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient.
  • a compound or composition of the invention may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer, which in some variations may be for the duration of the individual’s life.
  • the compound is administered on a daily or intermittent schedule.
  • the compound can be administered to an individual continuously (for example, at least once daily) over a period of time.
  • the dosing frequency can also be less than once daily, e.g., about a once weekly dosing.
  • the dosing frequency can be more than once daily, e.g., twice or three times daily.
  • the dosing frequency can also be intermittent, including a ‘drug holiday’ (e.g., once daily dosing for 7 days followed by no doses for 7 days, repeated for any 14 day time period, such as about 2 months, about 4 months, about 6 months or more). Any of the dosing frequencies can employ any of the compounds described herein together with any of the dosages described herein.
  • a drug holiday e.g., once daily dosing for 7 days followed by no doses for 7 days, repeated for any 14 day time period, such as about 2 months, about 4 months, about 6 months or more.
  • the compounds provided herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, may be administered to an individual via various routes, including, e.g., intravenous, intramuscular, subcutaneous, oral and transdermal.
  • a compound provided herein can be administered frequently at low doses, known as 'metronomic therapy,' or as part of a maintenance therapy using compound alone or in combination with one or more additional drugs.
  • Metronomic therapy or maintenance therapy can comprise administration of a compound provided herein in cycles.
  • Metronomic therapy or maintenance therapy can comprise intra-tumoral administration of a compound provided herein.
  • the invention provides a method of treating cancer in an individual by parenterally administering to the individual (e.g., a human) an effective amount of a compound or salt thereof.
  • the route of administration is intravenous, intra-arterial, intramuscular, or subcutaneous.
  • the route of administration is oral.
  • the route of administration is transdermal.
  • compositions including pharmaceutical compositions as described herein for the use in treating, preventing, and/or delaying the onset and/or development of cancer and other methods described herein.
  • the composition comprises a pharmaceutical formulation which is present in a unit dosage form.
  • articles of manufacture comprising a compound of the disclosure or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, composition, and unit dosages described herein in suitable packaging for use in the methods described herein.
  • suitable packaging is known in the art and includes, for example, vials, vessels, ampules, bottles, jars, flexible packaging and the like.
  • An article of manufacture may further be sterilized and/or sealed.
  • kits for carrying out the methods of the invention which comprises one or more compounds described herein or a composition comprising a compound described herein.
  • the kits may employ any of the compounds disclosed herein.
  • the kit employs a compound described herein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
  • the kits may be used for any one or more of the uses described herein, and, accordingly, may contain instructions for the treatment of cancer.
  • Kits generally comprise suitable packaging.
  • the kits may comprise one or more containers comprising any compound described herein.
  • Each component if there is more than one component
  • kits may be in unit dosage forms, bulk packages (e.g ., multi-dose packages) or sub-unit doses.
  • kits may be provided that contain sufficient dosages of a compound as disclosed herein and/or a second pharmaceutically active compound useful for a disease detailed herein to provide effective treatment of an individual for an extended period, such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or more.
  • Kits may also include multiple unit doses of the compounds and instructions for use and be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies).
  • kits may optionally include a set of instructions, generally written instructions, although electronic storage media (e.g., magnetic diskette or optical disk) containing instructions are also acceptable, relating to the use of component(s) of the methods of the present invention.
  • the instructions included with the kit generally include information as to the components and their administration to an individual.
  • IC 50 values of compounds against CDK4 and CDK6 are determined by luminescence using retinoblastoma as substrate.
  • Kinase assays are performed in kinase buffer (#PV6135, Invitrogen, Life Technologies Grand Island, NY) where total reaction volume is 30 ⁇ L/well in 96-well half area white plates (#3693, Costar).
  • 25xtest compounds at specific concentrations (e.g., final concentration range: 0.1 nM - 200 nM) is mixed with 10 ⁇ L of 2.5xkinase (5 nM, CDK4 #PR8064A and CDK6 #PR8422B,
  • Readings are taken at 15 min and 45 min incubation after detection reagent is added in a Synergy Neo Plate reader (BioTek, Winooski, VT) at single excitation of 340 nm and Dual emission at 495 nm and 520 nm respectively.
  • the following equations are used in the CDK4 and CDK6 assay data analysis. Percent inhibition (100 -% activity) is fitted to the “four-parameter logistic model” in XLfit for determination of IC 50 values.
  • IC 50 values of compounds against CDK1 are determined by Z'- LYTETM. These screening assays are performed at Invitrogen Life Technologies (Grand Island, NY) on a low volume NBS, black 384-well plate (#4514, Corning).
  • 0.1 ⁇ L of 100 x test compound in 100% DMSO (at specific solutions) is mixed with 2.4 ⁇ L of Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl 2 , 1 mM EGTA), 5 ⁇ L of 2x Kinase (3.5 - 46.4 ng CDK1/cyclin B)/Peptide (2 ⁇ M Ser/Thr 18), and 2.5 ⁇ L of 4xATP solution (34 ⁇ M).
  • Kinase Buffer 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl 2 , 1 mM EGTA
  • 2.5 ⁇ L of 4xATP solution 34 ⁇ M
  • Development Reagent Solution (5 ⁇ L of 1:1024 dilution) is added to the plates followed with another 30-second plate shake, and the plates are further incubated at room temperature for one hour. The plates are read on fluorescence plate reader with Dual emission at 445 nm and 520 nm.
  • IC 50 values of compounds against CDK2 are determined by Z'- LYTETM. These screening assays are performed at Invitrogen Life Technologies (Grand Island, NY) on a low volume NBS, black 384-well plate (#4514, Corning).
  • 0.1 ⁇ L of 100 x test compound in 100% DMSO (at specific solutions) is mixed with 2.4 ⁇ L of Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgCl 2 , 1 mM EGTA), 5 ⁇ L of 2x Kinase (E22 - 10.3 ng CDK2/cyclin A)/Peptide (2 ⁇ M Ser/Thr 12), and 2.5 ⁇ L of 4xATP solution (31 ⁇ M).
  • Kinase Buffer 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgCl 2 , 1 mM EGTA
  • 2.5 ⁇ L of 4xATP solution 31 ⁇ M
  • Development Reagent Solution (5 ⁇ L of 1:1024 dilution) is added to the plates followed with another 30-second plate shake and the plates are further incubated at room temperature for one hour. The plates are read on fluorescence plate reader with Dual emission at 445 nm and 520 nm.
  • IC 50 values of compounds against CDK5 are determined by Z'-LYTETM. These screening assays are performed at Invitrogen Life Technologies (Grand Island, NY) on a low volume NBS, black 384-well plate (#4514, Corning).
  • 0.1 ⁇ L of 100 x test compound in 100% DMSO (at specific solutions) is mixed with 2.4 ⁇ L of Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgCl 2 , 1 mM EGTA), 5 ⁇ L of 2x Kinase (0.18 - 2 ng CDK5/p25)/Peptide (2 ⁇ M Ser/Thr 12), and 2.5 ⁇ L of 4xATP solution (17 ⁇ M).
  • Kinase Buffer 50 mM HEPES pH 7.5, 0.01% BRU-35, 10 mM MgCl 2 , 1 mM EGTA
  • 2.5 ⁇ L of 4xATP solution 17.
  • the plates are shaken for 30 seconds, and incubated for 60 minutes at room temperature.
  • Development Reagent Solution (5 ⁇ L of 1:4096 dilution) is added to the plates followed with another 30- second plate shake and the plates are further incubated at room temperature for one hour. The plates are read on fluorescence plate reader with Dual emission at 445 nm and 520 nm.
  • FI Fluorescence Intensity
  • C 100% Average Coumarin emission signal of the 100% Phos.
  • C 0% Average Coumarin emission signal of the 0% Phos.
  • F 100% Average Fluorescein emission signal of the 100% Phos.
  • Control; F 0% Average Fluorescein emission signal of the 0% Phos.
  • DRI Development Reaction Interference;
  • TCFI Test Compound Fluorescence Interference
  • IC 50 values of compounds against CDK7 are determined by AdaptaTM Assay at Invitrogen Life Technologies (Grand Island, NY) where total reaction volume is 10 ⁇ L/well in low volume, white 384-well plate (#4512, Coming).
  • 0.100 ⁇ L of 100 x test compound in 100% DMSO (at specific solutions) is mixed with 2.4 ⁇ L of HEPES (30 mM), 2.5 ⁇ L of 4x ATP solution (153 ⁇ M) and 5 ⁇ L of 2x Substrate/Kinase mixture (the 2x CDK7/cyclin H/MNAT1 / CDK7/9tide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl 2 , 1 mM EGTA).
  • the final 10 ⁇ L Kinase Reaction consists of 5 - 38.75 ng CDK7/cyclin H/MNAT1 and 200 ⁇ M CDK7/9tide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl 2 , 0.5 mM EGTA.
  • the plates are shaken for 30 seconds, centrifuged for 1 min at 1000xg, and incubated for 60 minutes at room temperature.
  • Detection Mix prepared in TR-FRET Dilution Buffer; the Detection mix consists of EDTA (30 mM), Eu-anti-ADP antibody (6 nM) and ADP tracer, and contains the EC60 concentration of tracer for 5-150 ⁇ M ATP) is added to the plates followed with another 30-second plate shake and centrifugation for 1 min at 1000xg, and the plates are further incubated at room temperature for one hour. The plates are read on fluorescence plate reader with Dual emission at 615 nm and 665 nm.
  • the following equations are used for AdaptaTM Assay Data Analysis.
  • the ATP/ADP standard curve is fit to model number 205 (sigmoidal dose-response model) in XLfit.
  • the dose response curve is also curve fit to model number 205.
  • IC 50 values of compounds against CDK2 are determined by LanthaScreenTM Eu Kinase Binding Assay at Invitrogen Life Technologies (Grand Island, NY) where total reaction volume is 16 ⁇ L/well in low volume, white 384-well plates (#784207, Greiner).
  • IC 50 values of compounds against FMS kinase are determined by LanthaScreenTM Eu Kinase Binding Assay at Invitrogen (Life Technologies Grand Island, NY) where total reaction volume is 10 ⁇ L in low-volume 384-well plates (#4511, Coming). Serially diluted compounds (3-fold) are incubated with kinase (1.25 nM) for 10 min, following which a mixture of ATP (10 ⁇ M) (#A1852, Sigma, St-Louis, MO) and fluorescent-PolyGT substrate (200 nM) (#PV3610, Invitrogen, Life Technologies Grand Island, NY) is added and incubated in dark at room temperature for 1H.
  • IC 50 values of compounds against the PI3K ⁇ kinase are determined by an assay performed by Reaction Biology Corporation (Malvern, PA). Briefly, this assay is conducted in buffer (Tris-HCl 40 mM (pH7.5), Orthovanadate 3 mM, MgCl 2 20 mM, DTT 2 mM, CHAPS 0.05%, DMSO 1%). PI3K ⁇ kinase is added to the reaction solution and mixed gently.
  • test compounds in 100% DMSO are mixed with the kinase reaction mixture to achieve the final compounds at pre-defined concentrations (e.g., range - 0.5 nM to 100 ⁇ M) by Acoustic technology (Echo550; nanoliter range).
  • concentrations e.g., range - 0.5 nM to 100 ⁇ M
  • ATP is added into the reaction mixture to initiate the reaction followed by a 30-min incubation at 30°C.
  • ADP-Glo reagent After quenching the reaction with ADP-Glo reagent, the plates are incubated for 40 min. The Detection Mixture is added, and the plate is incubated for an additional 30 min. At the end of incubation, luminescence is measured. For data analysis, the luminescence is converted into ⁇ M ADP production based on ADP standard curves. The nonlinear regression to obtain the standard curve and IC 50 values is performed using GraphPad Prism (GraphPad Software, Inc., San Diego, CA).
  • IC 50 values of compounds against CDK12 are determined by KinaseProfilerTM radiometric protein kinase assay at Eurofins Pharma Discovery (Dundee, UK). Compounds are prepared to 50x final assay concentration in 100% DMSO. This working stock of the compound is added to the assay well as the first component in each reaction. CDK12/Cyclin K is diluted in buffer (20 mM TRIS, 0.2 mM EDTA, 0.1% b- mercaptoethanol, 0.01% Brij-35, 5% glycerol, 1 mg/ml BSA) prior to addition to the reaction mix.
  • CDK12/Cyclin K is incubated with 20 mM Tris/HCl pH 8.5, 0.2 mM EDTA, 300 ⁇ M RSRSRSRSRSRSR, 10 mM Magnesium acetate and [ ⁇ - 33 R-ATR] (specific activity and concentration as required).
  • the reaction is initiated by the addition of the Mg/ ATP mix. After incubation for 120 minutes at room temperature, the reaction is stopped by the addition of phosphoric acid to a concentration of 0.5%. 10 ⁇ l of the stopped reaction is spotted onto a P30 filtermat and washed four times for 4 minutes in 0.425% phosphoric acid and once in methanol prior to drying and scintillation counting. Results are calculated as a percentage of the mean kinase activity in positive control samples. Data are fitted in XLfit for determination of IC 50 values.
  • Example B2 Determination of potency of compounds in cancer cell proliferation assay as a single agent.
  • the effects of test compounds were studied in two breast cancer cell lines of different subtype.
  • the cancer cells (Table below) are harvested during the logarithmic growth period and counted. Cell concentrations are adjusted to the appropriate number with respective medium and 90 ⁇ L cell suspensions are added to 96-well plates. After cells are seeded, the plates are shaken gently to distribute cells evenly and incubated at 37 °C, 5% CO 2 on day 1.
  • Cells are treated with test compounds at 7 to 9 concentrations within a desired concentration range (e.g. 1.1 nM - 10 ⁇ M) on day 2 by series diluting the test compound stock solution (10 mM in DMSO) with culture medium. Treatment duration was 144H (with a medium change at 72H) for both MCF-7 and DU4475 cells. Cell viability is assessed by Cell Titer-Glo® as recommended by Promega (Cat. No.: G7572), or by resazurin assay (Sigma Aldrich, Cat. No.: R7017) post treatment.
  • a desired concentration range e.g. 1.1 nM - 10 ⁇ M
  • Treatment duration was 144H (with a medium change at 72H) for both MCF-7 and DU4475 cells.
  • Cell viability is assessed by Cell Titer-Glo® as recommended by Promega (Cat. No.: G7572), or by resazurin assay (Sigma Aldrich, Cat
  • test compounds are studied in additional cell lines of various histotypes, such as A549 lung adenocarcinoma, HCT-116 colorectal carcinoma, ZR-75-30 breast ductal carcinoma, Hs-578T breast epithelia carcinoma and BT-549 breast ductal carcinoma cells.
  • the cancer cells are harvested during the logarithmic growth period and counted. Cell concentrations are adjusted to the appropriate number with suitable medium, and 90 ⁇ L cell suspensions are added to 96-well plates. After cells are seeded, the plates are shaken gently to distribute cells evenly and incubated at 37 °C, 5% CO 2 on day 1. Cells are treated with test compounds at typically 7-9 concentrations within a desired concentration range (e.g.
  • test compounds are studied in the same and/or other cancer cell lines using similar proliferation methods with possible variations in cell seeding densities and/or incubation durations.
  • the cell cycle phase distribution post treatment of test compounds is studied using flow cytometer using DAPI staining.
  • Cellular senescence is evaluated after continuously treating cells for a long time (e.g., 14 days) followed by staining cells lines for Senescence associated- ⁇ -galactosidase (SA ⁇ GAL).
  • SA ⁇ GAL Senescence associated- ⁇ -galactosidase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés hétérocycliques en tant qu'inhibiteurs de CDK4 ou de CDK6 ou d'autres inhibiteurs de CDK. Les composés peuvent être utilisés en tant qu'agents thérapeutiques pour le traitement de maladies et peuvent trouver une utilisation particulière en oncologie.
PCT/US2022/072061 2021-05-03 2022-05-02 Composés hétérocycliques en tant qu'inhibiteurs de kinase WO2022236255A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183529P 2021-05-03 2021-05-03
US63/183,529 2021-05-03

Publications (2)

Publication Number Publication Date
WO2022236255A2 true WO2022236255A2 (fr) 2022-11-10
WO2022236255A3 WO2022236255A3 (fr) 2022-12-15

Family

ID=83932997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/072061 WO2022236255A2 (fr) 2021-05-03 2022-05-02 Composés hétérocycliques en tant qu'inhibiteurs de kinase

Country Status (1)

Country Link
WO (1) WO2022236255A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2467137A1 (fr) * 2009-08-19 2012-06-27 Ambit Biosciences Corporation Composés biaryles et procédés d utilisation de ceux-ci
EP2558474B1 (fr) * 2010-04-13 2015-11-25 Rigel Pharmaceuticals, Inc. Composés 2,4-pyrimidinediamine et leurs promédicaments, et leurs utilisations
US20130338142A1 (en) * 2012-06-14 2013-12-19 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
EP3680238A1 (fr) * 2012-10-04 2020-07-15 University of Utah Research Foundation Analogues substitués de n-(3-(pyrimidine-4-yl)phényle)acrylamide en tant qu'inhibiteurs de btk des récepteurs de la tyrosine kinase
WO2019161224A1 (fr) * 2018-02-15 2019-08-22 GiraFpharma LLC Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases

Also Published As

Publication number Publication date
WO2022236255A3 (fr) 2022-12-15

Similar Documents

Publication Publication Date Title
JP7015059B2 (ja) 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法
JP6789239B2 (ja) Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
JP2021098721A (ja) 置換キナゾリン化合物およびその使用方法
KR20210045998A (ko) 헤테로사이클릭 스피로 화합물 및 암 치료를 위한 그의 사용 방법
JP2022509830A (ja) がんを処置するための化合物およびその使用方法
WO2021030623A1 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase
JP2020521740A (ja) 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
EP2598508B1 (fr) Isoxazolo-quinazolines en tant que modulateurs de l'activité protéine kinase
AU2022200838A1 (en) Inhibitors of ACK1/TNK2 tyrosine kinase
US11332473B2 (en) Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors
WO2020210380A1 (fr) Composés hétérocycliques et leurs utilisations
WO2020210381A1 (fr) Composés hétérocycliques et leurs utilisations
WO2022082174A1 (fr) Composés hétérocycliques et leurs utilisations
US20230174545A1 (en) Heterocyclic compounds as bet inhibitors
WO2022236256A1 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase
EP4013753A1 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
WO2022236255A2 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase
WO2020210383A1 (fr) Composés hétérocycliques et leurs utilisations
WO2022236253A1 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase
WO2020210377A1 (fr) Composés hétérocycliques et leurs utilisations
WO2022236257A1 (fr) Composés hétérocycliques utilisés comme inhibiteurs de kinase
US20220259195A1 (en) Crystalline forms of a cyclin-dependent kinase inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22799780

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22799780

Country of ref document: EP

Kind code of ref document: A2